10.2 Antihypertensive Pharmacology & Exercise Hemodynamics

10.2 Antihypertensive Pharmacology & Exercise Hemodynamics

[!NOTE] Pharmacological Surveillance Mandate: Nearly every patient entering Phase II cardiac rehabilitation is prescribed multi-agent antihypertensive regimens. Clinicians must master drug mechanisms, anticipated exertional hemodynamic shifts, and adverse side-effect profiles to tailor exercise prescriptions, detect drug-induced instability, and prevent post-exercise syncope.

Antihypertensive pharmacotherapy lowers systemic vascular resistance, reduces blood volume, or modulates cardiac chronotropy and inotropy. While these mechanisms confer potent cardioprotection, they significantly alter hemodynamic responses to acute aerobic and resistance exercise. Understanding drug-exercise interactions allows clinicians to formulate safe, individualized exercise prescriptions.

---

Beta-Adrenergic Antagonists: Chronotropic Blunting & Glycemic Masking

Beta-blockers represent cornerstone therapy following acute myocardial infarction (AMI), coronary revascularization, and in heart failure with reduced ejection fraction (HFrEF).

Pharmacological Subclasses

• Cardioselective Beta-1 Blockers (e.g., Metoprolol succinate/tartrate, Atenolol, Bisoprolol): Selectively antagonize $\beta_1$-adrenergic receptors in cardiac nodal and myocardial tissue at standard doses, decreasing adenylyl cyclase activity and cyclic AMP (cAMP) production. This reduces resting and exercise sinus rates, AV nodal conduction velocity, and myocardial contractile force.
• Non-Selective Beta Blockers (e.g., Propranolol, Nadolol): Block both $\beta_1$ and $\beta_2$ receptors. Antagonism of vascular and bronchial $\beta_2$ receptors can induce peripheral vasoconstriction and bronchospasm in susceptible asthmatic patients.
• Vasodilating Beta Blockers (e.g., Carvedilol, Labetalol, Nebivolol): Carvedilol and labetalol provide combined non-selective beta-blockade plus peripheral $\alpha_1$-adrenergic blockade, inducing systemic arterial vasodilation. Nebivolol provides selective $\beta_1$-blockade paired with endothelial nitric oxide-mediated vasodilation, resulting in less peripheral coldness and erectile dysfunction.

Exercise Hemodynamic Consequences & RPE Prescription

• Chronotropic and Inotropic Attenuation: Beta-blockers reduce resting heart rate by 10 to 15 bpm and peak exercise heart rate and systolic blood pressure by 20% to 30%. Rate-pressure product (RPP) is markedly lowered, elevating the ischemic threshold and preventing exertional angina.
• Invalidation of Age-Predicted Formulas: Traditional formulas (e.g., $220 - \text{age}$, Tanaka, Karvonen Heart Rate Reserve) markedly overestimate exercise target heart rates in beta-blocked patients. A patient with a theoretical max HR of 160 bpm may peak at only 118 bpm.
• Prescription Mandate: Exercise intensity must be guided by measured parameters from an on-medication graded exercise test (GXT) or, more commonly, by the Borg 6–20 Rating of Perceived Exertion (RPE) scale. Clinicians target an RPE of 11 to 14 ("light" to "somewhat hard"), which corresponds closely to 40% to 70% of peak aerobic capacity despite severe chronotropic blunting.

Masking of Hypoglycemic Symptoms in Diabetes

In patients with concurrent diabetes mellitus, catecholamines normally trigger early warning signs of acute hypoglycemia: tachycardia, palpitations, anxiety, and tremors mediated via $\beta$-adrenergic receptors. Beta-blockers blunt these neurogenic warning signs, placing patients at risk of undetected neuroglycopenic coma. Crucially, diaphoresis (profuse sweating) is mediated by sympathetic cholinergic fibers acting on muscarinic receptors and is not blocked by beta-antagonists. Clinicians must teach diabetic patients that sweating is their primary symptom of hypoglycemia and mandate pre- and post-exercise blood glucose monitoring.

---

Renin-Angiotensin-Aldosterone System (RAAS) Blockers

ACE inhibitors and Angiotensin II Receptor Blockers (ARBs) represent first-line antihypertensive therapy in patients with diabetes, chronic kidney disease, myocardial infarction, and systolic dysfunction.

Mechanisms & Hemodynamic Profile

• ACE Inhibitors (e.g., Lisinopril, Enalapril, Ramipril): Inhibit the angiotensin-converting enzyme (kininase II), preventing conversion of angiotensin I to the potent vasoconstrictor angiotensin II and suppressing aldosterone secretion.
• Angiotensin Receptor Blockers (ARBs) (e.g., Losartan, Valsartan, Candesartan): Selectively block the angiotensin II type 1 ($\text{AT}_1$) receptor, mitigating vasoconstriction, aldosterone release, and vascular remodeling without inhibiting kininase II.
• Exercise Hemodynamics: RAAS blockers lower resting and exercise systolic and diastolic blood pressure through systemic afterload reduction without blunting normal exercise chronotropic or inotropic responses. Peak heart rate and stroke volume remain uninhibited.

Adverse Effects: Bradykinin Cough & Orthostasis

• The ACEi Cough: Inactivation of kininase II by ACE inhibitors causes accumulation of bradykinin and substance P in the pulmonary tree, provoking a persistent, dry, hacking nocturnal cough in 5% to 20% of patients. This side effect is completely non-cardiac but frequently mistaken by patients for congestive heart failure. Treatment requires cross-titration to an ARB, which does not impede bradykinin breakdown.
• Angioedema: A rare (0.1–0.7%) but potentially lethal complication of ACE inhibitors characterized by rapid non-pitting swelling of the lips, tongue, pharynx, and airway; absolute contraindication to rechallenge.
• Post-Exercise Orthostasis: By blocking angiotensin-mediated compensatory vasoconstriction, ACE inhibitors and ARBs predispose patients to post-exercise hypotension if exertion ceases abruptly.

---

Calcium Channel Blockers (CCBs): Dihydropyridines vs. Non-Dihydropyridines

Calcium channel blockers inhibit voltage-gated L-type calcium channels in vascular smooth muscle and cardiac myocytes, sub-divided into two clinically distinct pharmacological classes:

Exercise Implications

• Amlodipine and Dihydropyridines: Preserve normal chronotropic competence during exercise testing. The hallmark side effect—dependent pedal edema—results from preferential arteriolar vasodilation increasing capillary hydrostatic pressure; it is not fluid overload and does not respond to loop diuretics.
• Diltiazem and Verapamil: Cause significant negative chronotropy and inotropy. When co-administered with beta-blockers, they carry a high risk of profound symptomatic sinus bradycardia, severe AV block, or asystole during rehabilitation sessions.

---

Diuretic Agents & Mineralocorticoid Receptor Antagonists

Diuretics mobilize sodium and water through renal tubule transport inhibition, altering plasma volume, stroke volume, and serum electrolytes:

1. Thiazide & Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone):
   • Inhibit the $\text{Na}^+/\text{Cl}^-$ cotransporter in the distal convoluted tubule.
   • Electrolyte Shifts: Promote renal potassium and magnesium wasting, leading to hypokalemia (<3.5 mEq/L) and hypomagnesemia, which trigger myocardial membrane instability, PVCs, and dangerous ventricular tachydysrhythmias during exercise.
2. Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide):
   • Inhibit the $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ symporter in the thick ascending limb of the loop of Henle. Highly potent natriuretics used primarily in volume-overloaded heart failure patients.
   • Volume Depletion & Hypotension: Over-diuresis reduces left ventricular end-diastolic volume (preload), producing exertional lightheadedness, hemoconcentration, and reflex tachycardia.
3. Potassium-Sparing Diuretics & MRAs (e.g., Spironolactone, Eplerenone):
   • Competitive antagonists of aldosterone receptors in the cortical collecting tubule, preventing sodium retention and potassium secretion.
   • Hyperkalemia Risk: Can cause dangerous hyperkalemia (>5.0–5.5 mEq/L), particularly when co-prescribed with ACE inhibitors or in chronic kidney disease, predisposing to peaked T waves, widened QRS complexes, and heart block.

---

Vasodilators, Alpha-Blockers & The Active Cool-Down Mandate

Peripheral vasodilators (e.g., Hydralazine, Nitrates) and selective $\alpha_1$-adrenergic blockers (e.g., Doxazosin, Prazosin, Terazosin) reduce peripheral vascular resistance by relaxing vascular smooth muscle.

Sustained Exercise ───> Widespread Skeletal Muscle Vasodilation
                         │
Abrupt Stoppage ───────> Loss of Skeletal Muscle Venous Pump + Blocked Sympathetic Tone
                         │
Result ────────────────> Massive Venous Pooling ───> Precipitous Preload Drop ───> Syncope

The Post-Exercise Syncope Cascade

During exercise, up to 80% of cardiac output is shunted to active skeletal muscle beds. Venous return to the heart depends critically on the rhythmic compressive action of contracting skeletal muscles (the muscle pump). If a patient receiving vasodilators or alpha-blockers stops exercising abruptly (e.g., standing still immediately after stepping off a treadmill):

1. Blood pools massively in dilated capacitance veins of the lower limbs.
2. Vasodilators and alpha-blockers prevent rapid reflex vasoconstriction.
3. Venous return (preload) drops precipitously, collapsing stroke volume and cerebral perfusion pressure, resulting in orthostatic syncope.

Clinical Prevention

Clinicians must mandate an extended active, gradual cool-down of at least 5 to 10 minutes at low workloads (e.g., slow walking at 1.5 mph or unresisted pedaling) to maintain the skeletal muscle pump while systemic vascular resistance gradually readjusts.

---

Clinical Scenario: Polypharmacy & Post-Exercise Presyncope

Clinical Encounter: A 67-year-old male post-PCI for stable angina is enrolled in Phase II CR. His medication regimen includes metoprolol tartrate 50 mg BID, amlodipine 10 mg daily, lisinopril 20 mg daily, and doxazosin 4 mg at bedtime. During session #4, he completes 25 minutes of cycling at 60 watts (HR 92 bpm, SBP 132/78 mmHg, RPE 12). He immediately steps off the bike to walk toward the water fountain, takes four steps, and collapses into a chair with grey pallor, yawning, and diaphoresis. Telemetry shows sinus rhythm at 58 bpm; manual blood pressure is 74/48 mmHg.

Analysis & Intervention:

• Mechanism: The patient experienced severe post-exercise orthostasis caused by the combination of active skeletal muscle vasodilation, peripheral $\alpha_1$-blockade (doxazosin), arteriole dilation (amlodipine), and afterload reduction (lisinopril), combined with abrupt cessation of the muscle pump. The beta-blocker prevented compensatory tachycardia.
• Immediate Action: Clinicians immediately place the patient in the supine position with legs elevated above heart level, restoring venous return. Within 3 minutes, blood pressure rises to 110/68 mmHg, and mental clarity returns.
• Permanent Protocol Modification: The patient's exercise prescription is amended to enforce a mandatory 8-minute gradual active cycling cool-down at zero resistance, followed by seated blood pressure checks before standing.